Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager
The novel LABC-13F08 scFv exhibits a mode of binding to MSLN which is not observed in typical anti-MSLN antibodies. Efficacious targeting by a T cell secreted engager would represent a clinically differentiated approach for the treatment of MSLN<sup>+</sup> tumors.
Authors
- Paris Kosti (ORCID: https://orcid.org/0000-0002-8558-1064)
- George Coukos (ORCID: https://orcid.org/0000-0001-8813-7367)
- Steven M. Dunn (ORCID: https://orcid.org/0000-0002-7402-9581)
- Johan Abram-Saliba (ORCID: https://orcid.org/0000-0002-0945-8574)
- Melita Irving (ORCID: https://orcid.org/0000-0002-6849-7194)
- Evripidis Lanitis (ORCID: https://orcid.org/0000-0002-8194-5414)
- Laetitia Pericou-Troquier
- Sarah Pavelot
- Tiphaine Ruggeri
- Marc Laffaille
Institutions
- Ludwig Cancer Research (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1136/jitc-2024-010063
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- École Polytechnique Fédérale de Lausanne
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Université de Lausanne